Last reviewed · How we verify

Rocuronium 0.8

Ain Shams University · Phase 3 active Small molecule

Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively inhibits nicotinic acetylcholine receptors at the neuromuscular junction.

Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively inhibits nicotinic acetylcholine receptors at the neuromuscular junction. Used for Endotracheal intubation, Surgical procedures requiring muscle relaxation.

At a glance

Generic nameRocuronium 0.8
SponsorAin Shams University
Drug classNon-depolarizing neuromuscular blocking agent
TargetNicotinic acetylcholine receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

This inhibition prevents acetylcholine from binding to its receptor, leading to muscle paralysis. The effect is reversible with anticholinesterases or by allowing time for spontaneous recovery.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: